Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Cervical Cancer, August 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 150 articles:
HTML format


 

Single Articles

  1. LIN SM, Ku HY, Chang TC, Liu TW, et al
    The prognostic impact of overall treatment time on disease outcome in uterine cervical cancer patients treated primarily with concomitant chemoradiotherapy: a nationwide Taiwanese cohort study.
    Oncotarget. 2017 Jul 27. doi: 10.18632/oncotarget.19617.
    Abstract    

    Abstract available

  2. XU W, Mi Y, He P, He S, et al
    gamma-Tocotrienol Inhibits Proliferation and Induces Apoptosis Via the Mitochondrial Pathway in Human Cervical Cancer HeLa Cells.
    Molecules. 2017;22.
    Abstract    

    Abstract available

  3. HAILE ZT, Kingori C, Chavan B, Francescon J, et al
    Association Between Risky Sexual Behavior and Cervical Cancer Screening Among Women in Kenya: A Population-Based Study.
    J Community Health. 2017 Aug 3. doi: 10.1007/s10900-017-0410.
    Abstract    

    Abstract available

  4. LIU S, Liao G, Li G
    Regulatory effects of COL1A1 on apoptosis induced by radiation in cervical cancer cells.
    Cancer Cell Int. 2017;17:73.
    Abstract    

    Abstract available

  5. ZENG Y, Wang KX, Xu H, Hong Y, et al
    Integrative miRNA analysis identifies hsa-miR-3154, hsa-miR-7-3, and hsa-miR-600 as potential prognostic biomarker for cervical cancer.
    J Cell Biochem. 2017 Aug 3. doi: 10.1002/jcb.26315.
    Abstract    

    Abstract available

  6. BATOOL SA, Sajjad S, Malik H
    Cervical cancer in Pakistan: A review.
    J Pak Med Assoc. 2017;67:1074-1077.
    Abstract    

    Abstract available

  7. XU L, Xu Q, Li X, Zhang X, et al
    MicroRNA-21 regulates the proliferation and apoptosis of cervical cancer cells via tumor necrosis factor-alpha.
    Mol Med Rep. 2017 Aug 2. doi: 10.3892/mmr.2017.7143.
    Abstract    

    Abstract available

  8. WATSON M, Soman A, Flagg EW, Unger E, et al
    Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009-2012.
    Prev Med. 2017 Jul 29. pii: S0091-7435(17)30274.
    Abstract    

    Abstract available

  9. AWUA AK, Wiredu EK, Afari EA, Tijani AS, et al
    A tailored within-community specimen collection strategy increased uptake of cervical cancer screening in a cross-sectional study in Ghana.
    BMC Public Health. 2017;18:80.
    Abstract    

    Abstract available

  10. MOLLAEI H, Safaralizadeh R, Babaei E, Abedini MR, et al
    The anti-proliferative and apoptotic effects of crocin on chemosensitive and chemoresistant cervical cancer cells.
    Biomed Pharmacother. 2017;94:307-316.
    Abstract    

    Abstract available

  11. MACHIDA H, Moeini A, Ciccone MA, Mostofizadeh S, et al
    Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer.
    Am J Clin Oncol. 2017 Jul 31. doi: 10.1097/COC.0000000000000394.
    Abstract    

    Abstract available

  12. KOZASA K, Mabuchi S, Komura N, Yokoi E, et al
    Comparison of clinical utilities of the platelet count and platelet-lymphocyte ratio for predicting survival in patients with cervical cancer: a single institutional study and literature review.
    Oncotarget. 2017 Jul 25. doi: 10.18632/oncotarget.19560.
    Abstract    

    Abstract available

  13. WAKAYAMA A, Kudaka W, Nakasone T, Taira Y, et al
    Secondary uterine carcinosarcoma after concurrent chemoradiotherapy for cervical cancer: Case reports.
    Gynecol Oncol Rep. 2017;21:81-83.
    Abstract    

    Abstract available

  14. PARK JM, Park SY, Kim JI, Kang HC, et al
    A comparison of treatment plan quality between Tri-Co-60 intensity modulated radiation therapy and volumetric modulated arc therapy for cervical cancer.
    Phys Med. 2017 Jul 28. pii: S1120-1797(17)30207.
    Abstract    

    Abstract available

  15. PENG Y, Wang X, Feng H, Yan G, et al
    Is oral contraceptive use associated with an increased risk of cervical cancer? An evidence-based meta-analysis.
    J Obstet Gynaecol Res. 2017;43:913-922.
    Abstract    

    Abstract available

  16. HANPRASERTPONG J, Geater A, Jiamset I, Padungkul L, et al
    Fear of cancer recurrence and its predictors among cervical cancer survivors.
    J Gynecol Oncol. 2017 Jul 17. doi: 10.3802/jgo.2017.
    Abstract    

    Abstract available

  17. SALAZAR-AGUILAR S, Ruiz-Posadas LDM, Cadena-Iniguez J, Soto-Hernandez M, et al
    Sechium edule (Jacq.) Swartz, a New Cultivar with Antiproliferative Potential in a Human Cervical Cancer HeLa Cell Line.
    Nutrients. 2017;9.
    Abstract    

    Abstract available

  18. LU Z, Chen H, Zheng XM, Chen ML, et al
    Experimental study on the apoptosis of cervical cancer Hela cells induced by juglone through c-Jun N-terminal kinase/c-Jun pathway.
    Asian Pac J Trop Med. 2017;10:572-575.
    Abstract    

    Abstract available

  19. BANERJEE S
    Bevacizumab in cervical cancer: a step forward for survival.
    Lancet. 2017 Jul 27. pii: S0140-6736(17)31965.
    Abstract    



  20. TEWARI KS, Sill MW, Penson RT, Huang H, et al
    Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
    Lancet. 2017 Jul 27. pii: S0140-6736(17)31607.
    Abstract    

    Abstract available

  21. ZHANG J, Gao Y
    CCAT-1 promotes proliferation and inhibits apoptosis of cervical cancer cells via the Wnt signaling pathway.
    Oncotarget. 2017 Jul 10. doi: 10.18632/oncotarget.19155.
    Abstract    

    Abstract available

  22. HAN F, Li Y, Lu Q, Ma L, et al
    3-(2-Chloropropyl amide)-4-methoxy-N-phenylbenzamide inhibits expression of HPV oncogenes in human cervical cancer cell.
    Virol J. 2017;14:145.
    Abstract    

    Abstract available

  23. HEIDEGGER H, Dietlmeier S, Ye Y, Kuhn C, et al
    The Prostaglandin EP3 Receptor Is an Independent Negative Prognostic Factor for Cervical Cancer Patients.
    Int J Mol Sci. 2017;18.
    Abstract    

    Abstract available

  24. WAGNER W, Kania KD, Ciszewski WM
    Stimulation of lactate receptor (HCAR1) affects cellular DNA repair capacity.
    DNA Repair (Amst). 2017;52:49-58.
    Abstract    

    Abstract available

  25. KALINOWSKI P, Grzadziel A
    HPV Vaccinations in Lublin Region, Poland.
    Postepy Hig Med Dosw (Online). 2017;71:92-97.
    Abstract    

    Abstract available

  26. DILLEY S, Scarinci I, Kimberlin D, Straughn JM Jr, et al
    Preventing HPV-Related Cancers - We Are All In This Together.
    Am J Obstet Gynecol. 2017 Feb 21. pii: S0002-9378(17)30299.
    Abstract    

    Abstract available

  27. IVERSEN L, Sivasubramaniam S, Lee AJ, Fielding S, et al
    Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study.
    Am J Obstet Gynecol. 2017 Feb 8. pii: S0002-9378(17)30179.
    Abstract    

    Abstract available

  28. VISWANATHAN AN, Erickson BA, Ibbott GS, Small W Jr, et al
    The American College of Radiology and the American Brachytherapy Society practice parameter for the performance of low-dose-rate brachytherapy.
    Brachytherapy. 2017;16:68-74.
    Abstract    

    Abstract available

  29. ROUSSOS-ROSS K, Foster L, Peterson HV, Decesare J, et al
    Do Educational Seminars for the Human Papillomavirus Vaccine Improve Attitudes Toward the Value of Vaccination?
    J Pediatr Adolesc Gynecol. 2017;30:456-459.
    Abstract    

    Abstract available

  30. TALEBI S, Bolhassani A, Azad TM, Arashkia A, et al
    Immuno-Stimulating Peptide Derived from HMGB1 is More Effective Than the N-Terminal Domain of Gp96 as an Endogenous Adjuvant for Improvement of Protein Vaccines.
    Protein Pept Lett. 2017;24:190-196.
    Abstract    

    Abstract available

  31. SUNEJA G, Brown D, Chang A, Erickson B, et al
    American Brachytherapy Society: Brachytherapy treatment recommendations for locally advanced cervix cancer for low-income and middle-income countries.
    Brachytherapy. 2017;16:85-94.
    Abstract    

    Abstract available

  32. XU X, Mann JR, McDermott SW, Deroche CB, et al
    Women with Visual Impairment and Insured by Medicaid or Medicare Are Less Likely to Receive Recommended Screening for Breast and Cervical Cancers.
    Ophthalmic Epidemiol. 2017;24:168-173.
    Abstract    

    Abstract available

  33. TYAGI N, Suneja A, Mishra K, Jain S, et al
    Comparison of Keyes Punch Biopsy Instrument with Cervical Punch Biopsy Forceps for Diagnosing Cervical Lesions.
    Gynecol Obstet Invest. 2017;82:157-162.
    Abstract    

    Abstract available

  34. CUSCHIERI K, Geraets D, Cuzick J, Cadman L, et al
    Performance of a cartridge based assay for the detection of clinically significant HPV infection - lessons from VALGENT (Validation of HPV Genotyping Tests).
    J Clin Microbiol. 2016 Jul 6. pii: JCM.00897.
    Abstract    

    Abstract available

  35. VENTRIGLIA J, Paciolla I, Pisano C, Cecere SC, et al
    Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
    Cancer Treat Rev. 2017;59:109-116.
    Abstract    

    Abstract available

  36. BAZAZ M, Shahry P, Latifi SM, Araban M, et al
    Cervical Cancer Literacy in Women of Reproductive Age and Its Related Factors.
    J Cancer Educ. 2017 Aug 10. doi: 10.1007/s13187-017-1270.
    Abstract    

    Abstract available

  37. GUBBALA K, Laios A, Madhuri TK, Pathiraja P, et al
    Results from Survey to Assess Current Trends in Surgical Practice in the Management of Women with Early Stage Cervical Cancer within the BGCS Community with an Emphasis on Routine Frozen Section Examination.
    Int J Surg Oncol. 2017;2017:2962450.
    Abstract    

    Abstract available

  38. RAGAN KR, Buchanan Lunsford N, Lee Smith J, Saraiya M, et al
    Perspectives of Screening-Eligible Women and Male Partners on Benefits of and Barriers to Treatment for Precancerous Lesions and Cervical Cancer in Kenya.
    Oncologist. 2017 Aug 10. pii: theoncologist.2017-0053.
    Abstract    

    Abstract available

  39. OU L, Wang D, Zhang H, Yu Q, et al
    Decreased Expression of MiR-138-5p by LncRNA H19 in Cervical Cancer Promotes Tumor Proliferation.
    Oncol Res. 2017 Aug 10. doi: 10.3727/096504017X15017209042610.
    Abstract    

    Abstract available

  40. DENG YQ, Zhou XH, Jiang LL, Tang XJ, et al
    [Clinical significance of sigma1 receptor over-expression in cervical cancer and the effect of its synthetic ligands on the growth of cervical cancer cells].
    Zhonghua Fu Chan Ke Za Zhi. 2017;52:473-482.
    Abstract    

    Abstract available

  41. KOLIOPOULOS G, Nyaga VN, Santesso N, Bryant A, et al
    Cytology versus HPV testing for cervical cancer screening in the general population.
    Cochrane Database Syst Rev. 2017;8:CD008587.
    Abstract    

    Abstract available

  42. TANAKA Y, Ueda Y, Okazawa A, Kakuda M, et al
    'Smartscopy' as an alternative device for cervical cancer screening: a pilot study.
    BMJ Innov. 2017;3:123-126.
    Abstract    

    Abstract available

  43. GALLAY C, Girardet A, Viviano M, Catarino R, et al
    Cervical cancer screening in low-resource settings: a smartphone image application as an alternative to colposcopy.
    Int J Womens Health. 2017;9:455-461.
    Abstract    

    Abstract available

  44. LIANG Y, Liu J, Liu T, Yang X, et al
    Anti-c-Met antibody bioconjugated with hollow gold nanospheres as a novel nanomaterial for targeted radiation ablation of human cervical cancer cell.
    Oncol Lett. 2017;14:2254-2260.
    Abstract    

    Abstract available

  45. ZHU H, Chen X, Hu Y, Shi Z, et al
    Long non-coding RNA expression profile in cervical cancer tissues.
    Oncol Lett. 2017;14:1379-1386.
    Abstract    

    Abstract available

  46. WANG X, Wang Z, Wang J, Wang Y, et al
    LncRNA MEG3 has anti-activity effects of cervical cancer.
    Biomed Pharmacother. 2017;94:636-643.
    Abstract    

    Abstract available

  47. BATRAN RZ, Dawood DH, El-Seginy SA, Ali MM, et al
    New Coumarin Derivatives as Anti-Breast and Anti-Cervical Cancer Agents Targeting VEGFR-2 and p38alpha MAPK.
    Arch Pharm (Weinheim). 2017 Aug 8. doi: 10.1002/ardp.201700064.
    Abstract    

    Abstract available

  48. WANG J, Feng Y, Chen X, Du Z, et al
    SH3BP1-induced Rac-Wave2 pathway activation regulates cervical cancer cell migration, invasion and chemoresistance to cisplatin.
    J Cell Biochem. 2017 Aug 8. doi: 10.1002/jcb.26334.
    Abstract    

    Abstract available

  49. TAKEKUMA M, Mori K, Iida T, Kurihara K, et al
    The concept of platinum sensitivity could be applied to recurrent cervical cancer: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
    Cancer Chemother Pharmacol. 2017 Aug 7. doi: 10.1007/s00280-017-3402.
    Abstract    

    Abstract available

  50. TENJIMBAYASHI Y, Onuki M, Hirose Y, Mori S, et al
    Whole-genome analysis of human papillomavirus genotypes 52 and 58 isolated from Japanese women with cervical intraepithelial neoplasia and invasive cervical cancer.
    Infect Agent Cancer. 2017;12:44.
    Abstract    

    Abstract available

  51. LIU C, Ding L, Bai L, Chen X, et al
    Folate receptor alpha is associated with cervical carcinogenesis and regulates cervical cancer cells growth by activating ERK1/2/c-Fos/c-Jun.
    Biochem Biophys Res Commun. 2017 Aug 3. pii: S0006-291X(17)31551.
    Abstract    

    Abstract available

  52. CAMPBELL P, Casement M, Addley S, Dobbs S, et al
    Early catheter removal following laparoscopic radical hysterectomy for cervical cancer: assessment of a new bladder care protocol.
    J Obstet Gynaecol. 2017 Aug 6:1-3. doi: 10.1080/01443615.2017.1328668.
    Abstract    

    Abstract available

  53. DE ROSA N, Lavitola G, Giampaolino P, Morra I, et al
    Impact of Ospemifene on Quality of Life and Sexual Function in Young Survivors of Cervical Cancer: A Prospective Study.
    Biomed Res Int. 2017;2017:7513610.
    Abstract    

    Abstract available

  54. WANG ZL, Zhou W, Xiong ZA, Yu TH, et al
    Irreversible electroporation-mediated shRNA knockdown of the HPV18 E6 gene suppresses cervical cancer growth in vitro and in vivo.
    Oncol Lett. 2017;14:1943-1949.
    Abstract    

    Abstract available

  55. KORFAGE IJ, de Kwaadsteniet EW, van Voorst A, Stiggelbout AM, et al
    Preferences for cervical cancer screening: The role of implicit associations.
    Patient Educ Couns. 2017 Jul 27. pii: S0738-3991(17)30463.
    Abstract    

    Abstract available

  56. NOWAKOWSKI A, Wojciechowska U, Wieszczy P, Cybulski M, et al
    Trends in cervical cancer incidence and mortality in Poland: is there an impact of the introduction of the organised screening?
    Eur J Epidemiol. 2017 Aug 5. doi: 10.1007/s10654-017-0291.
    Abstract    

    Abstract available

  57. ZHAO HB, Zhang XF, Jia XL, Wang HB, et al
    Grb7 is over-expressed in cervical cancer and facilitate invasion and inhibit apoptosis in cervical cancer cells.
    Pathol Res Pract. 2017 Jul 26. pii: S0344-0338(16)30760.
    Abstract    

    Abstract available

  58. YANG W, Qiang JW, Tian HP, Chen B, et al
    Multi-parametric MRI in cervical cancer: early prediction of response to concurrent chemoradiotherapy in combination with clinical prognostic factors.
    Eur Radiol. 2017 Aug 4. doi: 10.1007/s00330-017-4989.
    Abstract    

    Abstract available

  59. VEGUNTA S, Files JA, Wasson MN
    Screening Women at High Risk for Cervical Cancer: Special Groups of Women Who Require More Frequent Screening.
    Mayo Clin Proc. 2017;92:1272-1277.
    Abstract    

    Abstract available

  60. KINJYO Y, Nagai Y, Toita T, Kudaka W, et al
    Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy for locally advanced squamous-cell carcinoma of the cervix: a retrospective analysis from a single institution.
    Br J Radiol. 2017;90:20170241.
    Abstract    

    Abstract available

  61. IIHOSHI H, Ishihara T, Kuroda S, Ishihara N, et al
    Aclarubicin, an anthracycline anti-cancer drug, fluorescently contrasts mitochondria and reduces the oxygen consumption rate in living human cells.
    Toxicol Lett. 2017;277:109-114.
    Abstract    

    Abstract available

  62. AIKO KY, Yoko M, Saito OM, Ryoko A, et al
    Accuracy of self-collected human papillomavirus samples from Japanese women with abnormal cervical cytology.
    J Obstet Gynaecol Res. 2017;43:710-717.
    Abstract    

    Abstract available

  63. YAMAGAMI W, Nagase S, Takahashi F, Ino K, et al
    Clinical statistics of gynecologic cancers in Japan.
    J Gynecol Oncol. 2017;28:e32.
    Abstract    

    Abstract available

  64. SUZUKI Y, Cho T, Mogami T, Yokota NR, et al
    Evaluation of endocervical curettage with conization in diagnosis of endocervical lesions.
    J Obstet Gynaecol Res. 2017;43:723-728.
    Abstract    

    Abstract available

  65. SUZUKI K, Furuhashi M, Kawamura T, Kubo M, et al
    Comparing Papanicolaou test results obtained during pregnancy and post-partum.
    J Obstet Gynaecol Res. 2017;43:705-709.
    Abstract    

    Abstract available

  66. VIVIANO M, Kenfack B, Catarino R, Tincho E, et al
    Feasibility of thermocoagulation in a screen-and-treat approach for the treatment of cervical precancerous lesions in sub-Saharan Africa.
    BMC Womens Health. 2017;17:2.
    Abstract    

    Abstract available

  67. VINOD SK, Lim K, Bell L, Veera J, et al
    High-risk CTV delineation for cervix brachytherapy: Application of GEC-ESTRO guidelines in Australia and New Zealand.
    J Med Imaging Radiat Oncol. 2017;61:133-140.
    Abstract    

    Abstract available

  68. LI Y, Carlson E, Villarreal R, Meraz L, et al
    Cost-effectiveness of a patient navigation program to improve cervical cancer screening.
    Am J Manag Care. 2017;23:429-434.
    Abstract    

    Abstract available

  69. PALAVALLI PARSONS LH, Roane B, Manders DB, Richardson DL, et al
    Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer.
    Am J Clin Oncol. 2017 Aug 16. doi: 10.1097/COC.0000000000000403.
    Abstract    

    Abstract available

  70. OKAZAWA-SAKAI M, Mabuchi S, Isohashi F, Kawashima A, et al
    Predictors of distant relapse in patients with FIGO stage IIB-IVA cervical cancer treated with definitive radiotherapy.
    J Obstet Gynaecol Res. 2017 Aug 17. doi: 10.1111/jog.13446.
    Abstract    

    Abstract available

  71. TSUJIKAWA T, Rahman T, Yamamoto M, Yamada S, et al
    18F-FDG PET radiomics approaches: comparing and clustering features in cervical cancer.
    Ann Nucl Med. 2017 Aug 16. doi: 10.1007/s12149-017-1199.
    Abstract    

    Abstract available

  72. ABAKPORO U, Hussein A, Begun JW, Shippee T, et al
    Knowledge, Beliefs and Attitudes of Somali Men in Olmsted County, Minnesota, U.S., on the Human Papillomavirus Vaccine and Cervical Cancer Screening: January 17, 2015.
    J Immigr Minor Health. 2017 Aug 16. doi: 10.1007/s10903-017-0642.
    Abstract    

    Abstract available

  73. LUO S, Li N, Yu S, Chen L, et al
    MicroRNA-92a promotes cell viability and invasion in cervical cancer via directly targeting Dickkopf-related protein 3.
    Exp Ther Med. 2017;14:1227-1234.
    Abstract    

    Abstract available

  74. HUANG Y, Huang H, Li M, Zhang X, et al
    MicroRNA-374c-5p regulates the invasion and migration of cervical cancer by acting on the Foxc1/snail pathway.
    Biomed Pharmacother. 2017;94:1038-1047.
    Abstract    

    Abstract available

  75. KAROLINA ZUK A, Wen X, Dilworth S, Li D, et al
    Modeling and validating three dimensional human normal cervix and cervical cancer tissues in vitro.
    J Biomed Res. 2017;31:240-247.
    Abstract    

    Abstract available

  76. MADZIMA TR, Vahabi M, Lofters A
    Emerging role of HPV self-sampling in cervical cancer screening for hard-to-reach women: Focused literature review.
    Can Fam Physician. 2017;63:597-601.
    Abstract    

    Abstract available

  77. DANKULCHAI P, Lohasammakul S, Petsuksiri J, Nakkrasae P, et al
    Dosimetric analysis and preliminary clinical result of image-guided brachytherapy with or without hybrid technique for cervical cancer using VariSource titanium ring applicator with "Siriraj Ring Cap".
    Brachytherapy. 2017 Aug 11. pii: S1538-4721(17)30409.
    Abstract    

    Abstract available

  78. LAI JC, Chen HH, Chu KH, Weng CS, et al
    Nationwide trends and in-hospital complications of trachelectomy for surgically resectable cervical cancer in Taiwanese women: A population-based study, 1998-2013.
    Taiwan J Obstet Gynecol. 2017;56:449-455.
    Abstract    

    Abstract available

  79. CHIANG YC, Chen YY, Hsieh SF, Chiang CJ, et al
    Screening frequency and histologic type influence the efficacy of cervical cancer screening: A nationwide cohort study.
    Taiwan J Obstet Gynecol. 2017;56:442-448.
    Abstract    

    Abstract available

  80. LUBOWICKA E, Gacuta E, Zajkowska M, Glazewska EK, et al
    [The plasma levels and diagnostic utility of matrix metalloproteinase-9 and CA 125 in cervical cancer patients].
    Pol Merkur Lekarski. 2017;43:10-14.
    Abstract    

    Abstract available

  81. LYNG H, Malinen E
    Hypoxia in cervical cancer: from biology to imaging.
    Clin Transl Imaging. 2017;5:373-388.
    Abstract    

    Abstract available

  82. NDIKOM CM, Ofi BA, Omokhodion FO, Bakare PO, et al
    Effects of Educational Intervention on Nurses' Knowledge and Attitude Towards Providing Cervical Cancer Screening Information in Selected Health Facilities in Ibadan, Nigeria.
    J Cancer Educ. 2017 Aug 11. doi: 10.1007/s13187-017-1267.
    Abstract    

    Abstract available

  83. DUAN S, Wu A, Chen Z, Yang Y, et al
    MiR-204 Regulates Cell Proliferation and Invasion by Targeting EphB2 in Human Cervical Cancer.
    Oncol Res. 2017 Aug 11. doi: 10.3727/096504017X15016337254641.
    Abstract    

    Abstract available

  84. FENG J
    Upregulation of MicroRNA-4262 Targets Kaiso (ZBTB33) to Inhibit the Proliferation and EMT of Cervical Cancer Cells.
    Oncol Res. 2017 Aug 11. doi: 10.3727/096504017X15021536183526.
    Abstract    

    Abstract available

  85. KURTZ JE, D'Hondt V, Lecuru F, Lhomme C, et al

    Bull Cancer. 2017;104 Suppl 1:S39-S42.
    Abstract    

    Abstract available

  86. JOLY F, Querleu D, Namer M, Pujade-Lauraine E, et al

    Bull Cancer. 2017;104 Suppl 1:S1-S5.
    Abstract    

    Abstract available

  87. CHAOUKI W, Mimouni M, Boutayeb S, Hachi H, et al
    [Evaluation of multidisciplinary team meeting; the example of gynecological mammary cancers in a tertiary referral center in Morocco].
    Bull Cancer. 2017;104.
    Abstract    

    Abstract available

  88. KRASHIAS G, Koptides D, Christodoulou C
    HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities.
    BMC Infect Dis. 2017;17:346.
    Abstract    

    Abstract available

  89. MUALLEM MZ, Henrich W, Braun T, Sehouli J, et al
    Therapeutic Pelvic Lymph Node Dissection in the Second Gestational Trimester: A Case Report and Literature Review.
    Anticancer Res. 2017;37:2487-2490.
    Abstract    

    Abstract available

  90. PRICE S
    A Second Shot at HPV.
    Tex Med. 2017;113:29-34.
    Abstract    

    Abstract available

  91. KRENGLI M, Pisani C, Deantonio L, Surico D, et al
    Intraoperative radiotherapy in gynaecological and genito-urinary malignancies: focus on endometrial, cervical, renal, bladder and prostate cancers.
    Radiat Oncol. 2017;12:18.
    Abstract    

    Abstract available

  92. JIANG C, Xu R, Li XX, Wang YY, et al
    p53R2 Overexpression in Cervical Cancer Promotes AKT Signaling and EMT, and Is Correlated with Tumor Progression, Metastasis and Poor Prognosis.
    Cell Cycle. 2017 Aug 25:0. doi: 10.1080/15384101.2017.1320629.
    Abstract    

    Abstract available

  93. WU X, Yang Z, Dang H, Peng H, et al
    Baicalein Inhibits the Proliferation of Cervical Cancer Cells Through the GSK3ss-Dependent Pathway.
    Oncol Res. 2017 Aug 23. doi: 10.3727/096504017X15031557924141.
    Abstract    

    Abstract available

  94. WANG HR, Liao GD, Chen W, Qiao YL, et al
    [Clinical value of p16/Ki-67 immunocytochemical dual staining in cervical cancer screening].
    Zhonghua Zhong Liu Za Zhi. 2017;39:636-640.
    Abstract    

    Abstract available

  95. DAPPA E, Elger T, Hasenburg A, Duber C, et al
    The value of advanced MRI techniques in the assessment of cervical cancer: a review.
    Insights Imaging. 2017 Aug 21. doi: 10.1007/s13244-017-0567.
    Abstract    

    Abstract available

  96. MORADI S, Tadris Hasani M, Darvish L, Roozbeh N, et al
    Evaluating Cervicovaginal Infections and Cervical Cancer in Women with Low Socioeconomic Levels.
    Iran J Public Health. 2017;46:867-868.
    Abstract    



  97. CADET TJ, Burke SL, Stewart K, Howard T, et al
    Cultural and emotional determinants of cervical cancer screening among older Hispanic women.
    Health Care Women Int. 2017 Aug 21:0. doi: 10.1080/07399332.2017.1364740.
    Abstract    



  98. ZAKARIAEE R, Hamarneh G, Brown CJ, Gaudet M, et al
    Association of bladder dose with late urinary side effects in cervical cancer high-dose-rate brachytherapy.
    Brachytherapy. 2017 Aug 16. pii: S1538-4721(17)30401.
    Abstract    

    Abstract available

  99. PAN JH, Wang HB, Du XF, Liu JY, et al
    [Polydatin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling pathway].
    Zhongguo Zhong Yao Za Zhi. 2017;42:2345-2349.
    Abstract    

    Abstract available

  100. TAY SK, Lin LE, Goh RC
    Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Ann Acad Med Singapore. 2017;46:267-273.
    Abstract    

    Abstract available

  101. SHANG QY, Wu CS, Gao HR
    Effects of DCK knockdown on proliferation, apoptosis and tumorigenicity in vivo of cervical cancer HeLa cells.
    Cancer Gene Ther. 2017 Aug 18. doi: 10.1038/cgt.2017.
    Abstract    

    Abstract available

  102. GHEBRE RG, Grover S, Xu MJ, Chuang LT, et al
    Cervical cancer control in HIV-infected women: Past, present and future.
    Gynecol Oncol Rep. 2017;21:101-108.
    Abstract    

    Abstract available

  103. HU Y, Wu JZ, Zhu H, Zhang SH, et al
    Association of HLA-DRB1, HLA-DQB1 Polymorphisms with HPV 16 E6 Variants among Young Cervical Cancer Patients in China.
    J Cancer. 2017;8:2401-2409.
    Abstract    

    Abstract available

  104. ZHAO N, Zhang G, He M, Huang H, et al
    SZRD1 is a Novel Protein that Functions as a Potential Tumor Suppressor in Cervical Cancer.
    J Cancer. 2017;8:2132-2141.
    Abstract    

    Abstract available

  105. MORISADA T, Teramoto K, Takano H, Sakamoto I, et al
    CITRUS, cervical cancer screening trial by randomization of HPV testing intervention for upcoming screening: Design, methods and baseline data of 18,471 women.
    Cancer Epidemiol. 2017;50.
    Abstract    

    Abstract available

  106. BROWN KGM, Solomon MJ, Koh CE
    Pelvic Exenteration Surgery: The Evolution of Radical Surgical Techniques for Advanced and Recurrent Pelvic Malignancy.
    Dis Colon Rectum. 2017;60:745-754.
    Abstract    

    Abstract available

  107. DE OLIVEIRA GR, Vieira VC, Avila EC, Finger-Jardim F, et al
    Human papillomavirus type distribution and HPV16 intratype diversity in southern Brazil in women with and without cervical lesions.
    Mem Inst Oswaldo Cruz. 2017;112:492-498.
    Abstract    

    Abstract available

  108. RICKMAN DS, Beltran H, Demichelis F, Rubin MA, et al
    Biology and evolution of poorly differentiated neuroendocrine tumors.
    Nat Med. 2017;23:1-10.
    Abstract    

    Abstract available

  109. YU J, Zhu HT, Zhao JJ, Su JZ, et al
    [Sorting role of p16(INK4a)/Ki-67 double immunostaining in the cervical cytology specimens of ASCUS and LSIL cases].
    Zhonghua Bing Li Xue Za Zhi. 2017;46:323-326.
    Abstract    

    Abstract available

  110. TANG Y, Zheng L, Yang S, Li B, et al
    Epidemiology and genotype distribution of human papillomavirus (HPV) in Southwest China: a cross-sectional five years study in non-vaccinated women.
    Virol J. 2017;14:84.
    Abstract    

    Abstract available

  111. TSHOMO U, Franceschi S, Tshokey T, Tobgay T, et al
    Evaluation of the performance of Human Papillomavirus testing in paired urine and clinician-collected cervical samples among women aged over 30 years in Bhutan.
    Virol J. 2017;14:74.
    Abstract    

    Abstract available

  112. GERVAIS F, Dunton K, Jiang Y, Largeron N, et al
    Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend.
    BMC Public Health. 2017;17:283.
    Abstract    

    Abstract available

  113. FONTECHA N, Nieto MC, Andia D, Cisterna R, et al
    RNA extraction method is crucial for human papillomavirus E6/E7 oncogenes detection.
    Virol J. 2017;14:50.
    Abstract    

    Abstract available

  114. JOLLY PE, Mthethwa-Hleta S, Padilla LA, Pettis J, et al
    Screening, prevalence, and risk factors for cervical lesions among HIV positive and HIV negative women in Swaziland.
    BMC Public Health. 2017;17:218.
    Abstract    

    Abstract available

  115. SARNIK J, Czubatka-Bienkowska A, Macieja A, Bielski R, et al
    The induction of oxidative stress in cervix carcinoma cells by levoglucosenone derived 4-S-salicyl derivative and (1-4)-S-thio-disaccharides. Part 4.
    Bioorg Med Chem Lett. 2017;27:1215-1219.
    Abstract    

    Abstract available

  116. ZHAO M, Li Y, Wei X, Zhang Q, et al
    Negative immune factors might predominate local tumor immune status and promote carcinogenesis in cervical carcinoma.
    Virol J. 2017;14:5.
    Abstract    

    Abstract available

  117. BANISTER CE, Liu C, Pirisi L, Creek KE, et al
    Identification and characterization of HPV-independent cervical cancers.
    Oncotarget. 2017;8:13375-13386.
    Abstract    

    Abstract available

  118. NORRELL LL, Kuppermann M, Moghadassi MN, Sawaya GF, et al
    Women's beliefs about the purpose and value of routine pelvic examinations.
    Am J Obstet Gynecol. 2017;217:86.
    Abstract    

    Abstract available

  119. PALEFSKY JM
    Human papillomavirus-associated anal and cervical cancers in HIV-infected individuals: incidence and prevention in the antiretroviral therapy era.
    Curr Opin HIV AIDS. 2017;12:26-30.
    Abstract    

    Abstract available

  120. ZIEMKE P
    p16/Ki-67 Immunocytochemistry in Gynecological Cytology: Limitations in Practice.
    Acta Cytol. 2017;61:230-236.
    Abstract    

    Abstract available

  121. NAYAR R, Wilbur DC
    The Bethesda System for Reporting Cervical Cytology: A Historical Perspective.
    Acta Cytol. 2017;61.
    Abstract    

    Abstract available

  122. OSAMURA RY
    A Groundbreaking Work Which Laid the Foundation for Mass Screening in Cervical Cytology in Japan.
    Acta Cytol. 2017;61.
    Abstract    

    Abstract available

  123. WILBUR DC
    Dr. Bibbo's Presidential Address on Automation in Cytology: Were Her Predictions Right, Wrong, or Somewhere in the Middle?
    Acta Cytol. 2017;61.
    Abstract    

    Abstract available

  124. CHANTZIANTONIOU N, Donnelly AD, Mukherjee M, Boon ME, et al
    Inception and Development of the Papanicolaou Stain Method.
    Acta Cytol. 2017;61.
    Abstract    

    Abstract available

  125. PATADJI S, Li Z, Pradhan D, Zhao C, et al
    Significance of high-risk HPV detection in women with atypical glandular cells on Pap testing: Analysis of 1857 cases from an academic institution.
    Cancer. 2016 Oct 24. doi: 10.1002/cncy.21791.
    Abstract    

    Abstract available

  126. BENEVOLO M, Allia E, Gustinucci D, Rollo F, et al
    Interobserver reproducibility of cytologic p16INK4a /Ki-67 dual immunostaining in human papillomavirus-positive women.
    Cancer. 2017;125:212-220.
    Abstract    

    Abstract available

  127. HOCKEL M, Wolf B, Hentschel B, Horn LC, et al
    Surgical treatment and histopathological assessment of advanced cervicovaginal carcinoma: A prospective study and retrospective analysis.
    Eur J Cancer. 2017;70:99-110.
    Abstract    

    Abstract available

  128. MIRGHANI H, Jung AC, Fakhry C
    Primary, secondary and tertiary prevention of human papillomavirus-driven head and neck cancers.
    Eur J Cancer. 2017;78:105-115.
    Abstract    

    Abstract available

  129. MOITRY M, Jegu J, Averous G, Velten M, et al
    Reporting reactive cellular changes on smears among women who undergo cervical cancer screening: results of a cohort study after seven years of follow-up.
    Eur J Obstet Gynecol Reprod Biol. 2017;216:232-238.
    Abstract    

    Abstract available

  130. HEIJKOOP ST, Nout RA, Quint S, Mens JWM, et al
    Dynamics of patient reported quality of life and symptoms in the acute phase of online adaptive external beam radiation therapy for locally advanced cervical cancer.
    Gynecol Oncol. 2017 Aug 19. pii: S0090-8258(17)31247.
    Abstract    

    Abstract available

  131. VELENTZIS LS, Caruana M, Simms KT, Lew JB, et al
    How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccina
    Int J Cancer. 2017 Aug 12. doi: 10.1002/ijc.30926.
    Abstract    

    Abstract available

  132. MABUCHI S, Kozasa K, Kimura T
    Radical hysterectomy after radiotherapy for recurrent or persistent cervical cancer.
    Int J Gynaecol Obstet. 2017 Jul 28. doi: 10.1002/ijgo.12284.
    Abstract    

    Abstract available

  133. GIANNELLA L, Fodero C, Boselli F, Rubino T, et al
    Age-related changes in pre- and post-conization HPV genotype distribution among women with high-grade cervical intraepithelial neoplasia.
    Int J Gynaecol Obstet. 2017 Jan 27. doi: 10.1002/ijgo.12106.
    Abstract    

    Abstract available

  134. FIELDS EC, Melvani R, Hajdok G, D'Souza D, et al
    A Multi-institution, Retrospective Analysis of Cervix Intracavitary Brachytherapy Treatments. Part 1: Is EQD2 Good Enough for Reporting Radiobiological Effects?
    Int J Radiat Oncol Biol Phys. 2017;99:219-226.
    Abstract    

    Abstract available

  135. CORY L, Latif N, Brensinger C, Zhang X, et al
    Readmission After Gynecologic Surgery: A Comparison of Procedures for Benign and Malignant Indications.
    Obstet Gynecol. 2017 Jul 7. doi: 10.1097/AOG.0000000000002141.
    Abstract    

    Abstract available

  136. BREBI P, Ili CG, Andana A, Menzel D, et al
    Frequency of Human papillomavirus in women attending cervical cancer screening program in Chile.
    BMC Cancer. 2017;17:518.
    Abstract    

    Abstract available

  137. LI J, Ning NY, Rao QX, Chen R, et al
    Pretreatment glycemic control status is an independent prognostic factor for cervical cancer patients receiving neoadjuvant chemotherapy for locally advanced disease.
    BMC Cancer. 2017;17:517.
    Abstract    

    Abstract available

  138. WANG W, Hou X, Yan J, Shen J, et al
    Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    BMC Cancer. 2017;17:510.
    Abstract    

    Abstract available

  139. WANG L, Wang P, Ren Y, Du J, et al
    Prevalence of High-Risk Human Papillomavirus (HR-HPV) Genotypes and Multiple Infections in Cervical Abnormalities from Northern Xinjiang, China.
    PLoS One. 2016;11:e0160698.
    Abstract    

    Abstract available

  140. KHUNAMORNPONG S, Settakorn J, Sukpan K, Suprasert P, et al
    Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand.
    PLoS One. 2016;11:e0158184.
    Abstract    

    Abstract available

  141. SMELOV V, Gheit T, Sundstrom K, Ploner A, et al
    Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Adenocarcinoma Risk: Nested Case-Control Study.
    PLoS One. 2016;11:e0156215.
    Abstract    

    Abstract available

  142. CHONGTHAWONSATID S
    Inequity of healthcare utilization on mammography examination and Pap smear screening in Thailand: Analysis of a population-based household survey.
    PLoS One. 2017;12:e0173656.
    Abstract    

    Abstract available

  143. JIANG Y, Chen C, Li L
    Comparison of Cold-Knife Conization versus Loop Electrosurgical Excision for Cervical Adenocarcinoma In Situ (ACIS): A Systematic Review and Meta-Analysis.
    PLoS One. 2017;12:e0170587.
    Abstract    

    Abstract available

  144. NOGUEIRA DIAS GENTA ML, Martins TR, Mendoza Lopez RV, Sadalla JC, et al
    Multiple HPV genotype infection impact on invasive cervical cancer presentation and survival.
    PLoS One. 2017;12:e0182854.
    Abstract    

    Abstract available

  145. KELLY HA, Ngou J, Chikandiwa A, Sawadogo B, et al
    Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa.
    PLoS One. 2017;12:e0174117.
    Abstract    

    Abstract available

  146. DEL MISTRO A, Frayle H, Rizzi M, Fantin G, et al
    Methylation analysis and HPV genotyping of self-collected cervical samples from women not responding to screening invitation and review of the literature.
    PLoS One. 2017;12:e0172226.
    Abstract    

    Abstract available

  147. DE GROOT AS, Tounkara K, Rochas M, Beseme S, et al
    Knowledge, attitudes, practices and willingness to vaccinate in preparation for the introduction of HPV vaccines in Bamako, Mali.
    PLoS One. 2017;12:e0171631.
    Abstract    

    Abstract available

  148. LEVENTAKOS K, Tsiodras S, Kelesidis T, Kefala M, et al
    gammaH2Ax Expression as a Potential Biomarker Differentiating between Low and High Grade Cervical Squamous Intraepithelial Lesions (SIL) and High Risk HPV Related SIL.
    PLoS One. 2017;12:e0170626.
    Abstract    

    Abstract available

  149. SIMMS KT, Hall M, Smith MA, Lew JB, et al
    Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.
    PLoS One. 2017;12:e0163509.
    Abstract    

    Abstract available

  150. SETIAWAN D, Kotsopoulos N, Wilschut JC, Postma MJ, et al
    Assessment of the Broader Economic Consequences of HPV Prevention from a Government-Perspective: A Fiscal Analytic Approach.
    PLoS One. 2016;11:e0160707.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Cervical Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;